U.S. markets extend AI-led gains as Paramount merger, OpenAI policy and Lilly demand stay in focus

U.S. markets extend AI-led gains as Paramount merger, OpenAI policy and Lilly demand stay in focus
AI drives market rally

U.S. investors head into Tuesday with stock futures higher after Wall Street posts broad gains led by artificial intelligence shares and a record Nasdaq close. The trading backdrop also includes merger progress in media, fresh debate over AI regulation, disruption to White House press access and new signs of demand in the GLP-1 drug market.

Highlights

  • Nasdaq Composite rises 2.26% to a record close and S&P 500 posts best day since August, driven by AI-related gains and lower yields.
  • Paramount Skydance settles with state attorneys general on its $110 billion Warner Bros. Discovery merger, targeting deal closure in about two weeks.
  • Eli Lilly CEO reports 700,000 new Medicare-covered seniors on GLP-1 drugs since July, with 70% using Lilly products and one-third on Foundayo.

Premarket drivers shape the trading agenda

As reported by CNBC, Monday’s rally is lifting sentiment into the new session as investors respond to strength in artificial intelligence-linked stocks, lower oil prices and easing Treasury yields.

The Nasdaq Composite rises 2.26% for a record close, its first since June, while the S&P 500 records its best day since early August. Advanced Micro Devices reaches a $1 trillion market capitalization for the first time during a five-day winning streak, and Meta shares jump more than 11% as its Muse AI personal agent app draws positive early attention. Bitcoin also moves above $86,000, its highest level since January, even after the Clarity Act is blocked in the Senate last week.

In media, Paramount Skydance reaches a settlement with a group of state attorneys general that had challenged its $110 billion merger with Warner Bros. Discovery. California Attorney General Rob Bonta says Paramount commits to increasing domestic production and accepts certain conditions for theatrical releases, while the company also says it will create a new board focused on editorial independence for CBS and CNN. According to a memo obtained by CNBC, Paramount CEO David Ellison tells employees the company is aiming to close the deal in about two weeks.

Policy, access and healthcare demand add sector pressure points

OpenAI publishes a new set of safety and security proposals for AI development, calling for global cooperation on standards for frontier models. The proposals arrive hours after Treasury Secretary Scott Bessent says developers need to take responsibility for themselves rather than expect a federal liability shield, while President Donald Trump says the Department of Justice and other U.S. law enforcement agencies will rein in AI if necessary, even as he downplays the technology’s dangers.

In Washington, the White House television press pool suspends coverage after CNN, the assigned TV pooler for Trump’s trip to New York for the United Nations General Assembly, is barred from serving in the pool. CNN, MS NOW and Politico file a lawsuit against Trump seeking to overturn White House bans affecting the three outlets, and a judge schedules the first hearing for Wednesday afternoon. The dispute raises questions about the continuity of presidential coverage and the public flow of information.

Healthcare investors are also watching Eli Lilly after CEO Dave Ricks says 700,000 new seniors start GLP-1 treatments since Medicare begins covering obesity drugs in July, with 70% of those patients using Lilly medicines. Ricks also says one-third of new GLP-1 pill patients are taking Foundayo, underscoring Lilly’s push to strengthen its position in a market led by Novo.

In our earlier coverage of the AI-driven tech rally led by Meta’s Muse assistant, we highlighted how strong demand for the new agent helped propel Meta higher and pushed the Nasdaq and chip stocks toward fresh records. We also noted that the upbeat equity move was reinforced by softer oil prices, even as investors weighed a busy geopolitical calendar that could sway risk sentiment.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.